Curis Inc CRIS Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$0.91 up $0.06, 6.65% at close Nov 6
Last close · Previous close $0.85
- Market cap
- At the Nov 6 close
- P/E ratio
- PausedOn last 12 months’ EPS
See the note under the price. - Diluted EPS
- PausedLast 12 months
See the note under the price. - Dividend yield
- NoneLast 12 months
Price chart
$0.91up $0.06, 6.65%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$0.85Nov 5
- Volume2.46MNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume11.50MLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $0.33 to $28.40; now $0.91
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
CRIS beat the S&P 500 in 1 of 7 periods.
| Period | CRIS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRIS: up 21.0% S&P 500: down 5.6% | CRIS beat the S&P 500 by 26.6 percentage points Beat |
| 3M | CRIS: down 79.4% S&P 500: down 4.1% | CRIS trailed the S&P 500 by 75.3 percentage points Trailed |
| YTD | CRIS: down 95.4% S&P 500: up 8.7% | CRIS trailed the S&P 500 by 104.1 percentage points Trailed |
| 1Y | CRIS: down 96.9% S&P 500: up 10.9% | CRIS trailed the S&P 500 by 107.8 percentage points Trailed |
| Long term | ||
| 3Y | CRIS: down 99.2% S&P 500: up 75.0% −79.6% vs +20.5% a year | CRIS trailed the S&P 500 by 174.2 percentage points Trailed |
| 5Y | CRIS: down 100.0% S&P 500: up 67.8% −79.5% vs +10.9% a year | CRIS trailed the S&P 500 by 167.8 percentage points Trailed |
| 10Y | CRIS: down 100.0% S&P 500: up 313.1% −57.6% vs +15.2% a year | CRIS trailed the S&P 500 by 413.1 percentage points Trailed |
$10,000 invested in CRIS 10 years ago (Nov 4, 2016) would be worth about $2 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
CRIS beat the S&P 500 in 1 of 7 periods.
| Period | CRIS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | CRIS: up 21.0% S&P 500: down 5.6% | CRIS beat the S&P 500 by 26.6 percentage points Beat |
| 3M | CRIS: down 79.4% S&P 500: down 4.3% | CRIS trailed the S&P 500 by 75.1 percentage points Trailed |
| YTD | CRIS: down 95.4% S&P 500: up 7.8% | CRIS trailed the S&P 500 by 103.2 percentage points Trailed |
| 1Y | CRIS: down 96.9% S&P 500: up 9.7% | CRIS trailed the S&P 500 by 106.6 percentage points Trailed |
| Long term | ||
| 3Y | CRIS: down 99.2% S&P 500: up 68.8% −79.6% vs +19.1% a year | CRIS trailed the S&P 500 by 168.0 percentage points Trailed |
| 5Y | CRIS: down 100.0% S&P 500: up 56.9% −79.5% vs +9.4% a year | CRIS trailed the S&P 500 by 156.9 percentage points Trailed |
| 10Y | CRIS: down 100.0% S&P 500: up 252.6% −57.6% vs +13.4% a year | CRIS trailed the S&P 500 by 352.6 percentage points Trailed |
$10,000 invested in CRIS 10 years ago (Nov 4, 2016) would be worth about $2 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$48,760.00
Closing high on . Now 100.0% below that record.
Split-adjusted daily closes since Aug 1, 2000.
Stock splits
3
Latest: 1-for-20 on . Share counts adjust after each split.
All 3 splits
- 1-for-20
- 1-for-20
- 1-for-5
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $4.31Mdown 62.2%
- Net income
- −$21.15M
- Diluted EPS
- PausedSee the note under the price.
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $2.93M | −$10.09M | Paused See the note under the price. |
| Q4 FY24 (Dec 31, 2024) | $3.35M | −$9.62M | Paused See the note under the price. |
| Q1 FY25 (Mar 31, 2025) | $2.38M | −$10.62M | Paused See the note under the price. |
| Q2 FY25 (Jun 30, 2025) | $2.75M | −$8.59M | Paused See the note under the price. |
| Q3 FY25 (Sep 30, 2025) | $3.18M | −$7.73M | Paused See the note under the price. |
| Q4 FY25 (Dec 31, 2025) | $1.14M | $19.36M | Paused See the note under the price. |
| Q1 FY26 (Mar 31, 2026) | $0.00 | −$24.20M | Paused See the note under the price. |
| Q2 FY26 (Jun 30, 2026) | $0.00 | −$8.58M | Paused See the note under the price. |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $10.65M | −$45.44M | Paused See the note under the price. |
| FY22 (Dec 31, 2022) | $10.16M | −$56.67M | Paused See the note under the price. |
| FY23 (Dec 31, 2023) | $10.02M | −$47.41M | Paused See the note under the price. |
| FY24 (Dec 31, 2024) | $10.91M | −$43.39M | Paused See the note under the price. |
| FY25 (Dec 31, 2025) | $9.44M | −$7.58M | Paused See the note under the price. |
Margins
- Gross 99.7%
- Operating −203.2%
- Net −490.3%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- −$30.59MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow−$30.59MLast 12 months
- Capital spending$0.00Last 12 months
- −709.0%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $24.59MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$0.00Last 12 months
Balance sheet
- $5.62MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$1.04MAs of Jun 30, 2026
- Net cash$4.57MAs of Jun 30, 2026
- Book value per sharePausedAs of Jun 30, 2026
See the note under the price. - 0.49As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.22As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 3 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✗Operating cash flow was positive: not passed
- ✓Return on assets improved: passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- −1,035.3%Last 12 months
Over the last 12 months, Curis lost money: its net loss was 1,035.3% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −87.9%Last 12 months
Over the last 12 months, Curis’s net loss was 87.9% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Curis Inc
Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 and FLT3 inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor, ibrutinib, in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in the TakeAim CLL Phase 2 study (CA-4948-203) of emavusertib in combination with the BTK inhibitor, zanubrutinib, in chronic lymphocytic leukemia (CLL). The Company's monotherapy and combination studies in acute myeloid leukemia (AML) are substantially complete, with additional funding the Company plans to continue development of emavusertib in AML. Emavusertib has received Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of PCNSL, AML and MDS and from the European Commission for the treatment of PCNSL. Curis, through its 2015 collaboration with Aurigene Discovery Technologies Limited, has the exclusive license to emavusertib (CA-4948).
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Massachusetts, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
CRIS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
CRIS stock FAQ
What is CRIS stock’s price today?
Curis (CRIS) traded at $0.91 at the close on , up $0.06 (6.65%) from the previous close of $0.85. Over the past 52 weeks it has traded between $0.33 and $28.40.
If you invested $1,000 in CRIS 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in CRIS on would be worth about $0 at the close on , a total return of −100.0%. The same $1,000 would be worth $0 if invested five years ago, $31 if invested one year ago, and $0 if invested 20 years ago. Past performance doesn’t predict future returns.
How much revenue does Curis make?
Curis reported $4.3 million of revenue over the four quarters to , down 62.2% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $0.0 thousand, down 100.0% from a year earlier.
Is Curis profitable?
Not over the four quarters to . Curis reported a net loss of $21.2 million across those four quarters on $4.3 million of revenue.
Does CRIS pay a dividend?
Curis hasn’t paid a dividend in the last twelve months.
What is CRIS’s 52-week high and low?
Over the past 52 weeks CRIS has traded as low as $0.33 and as high as $28.40. At $0.91 at the close on , it is 96.8% below that high and 178.9% above the low.
What is CRIS’s all-time high?
CRIS’s highest closing price was $48,760.00 on , adjusted for stock splits. At $0.91 at the close on , it is 100.0% below that record.
Has CRIS stock ever split?
Yes, three times: 1-for-5 on ; 1-for-20 on ; 1-for-20 on .
How has CRIS stock performed?
Including dividends and measured to the close on , CRIS has returned −95.4% so far this year and −96.9% over the past year, and −100.0% over five years (−79.5% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Curis in?
Curis is in the Healthcare sector and the Biotechnology industry, and is headquartered in Massachusetts, USA.
What exchange does CRIS trade on?
Curis trades on the Nasdaq under the ticker symbol CRIS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.